Navigation Links
BioMarin Announces Program for ERT for Treatment of MPS IVA - Morquio A Syndrome
Date:6/5/2008

bout MPS IVA

Mucopolysaccharidosis IVA (MPS IVA, also known as Morquio A Syndrome) is a disease characterized by deficient activity of N-acetylgalactosamine-6- sulfatase (GALNS) causing excessive lysosomal storage of keratan sulfate (KS). This excessive storage causes a systemic skeletal dysplasia, short stature, and joint abnormalities, which limit mobility and endurance. Malformation of the thorax impairs respiratory function, and odontoid hypoplasia and ligamentous laxity cause cervical spinal instability and potentially cord compression. Other symptoms may include hearing loss, corneal clouding, and heart valvular disease. Initial symptoms often become evident in the first five years of life. Depending on severity of the disease, age of diagnosis will vary.

The rate of incidence of MPS IVA is as yet unconfirmed, but estimates vary between 1 in 200,000 live births to 1 in 300,000 live births. Approximately 370 patients worldwide are currently registered in The International Morquio Organization (IMO) survey. An estimated 1,100 patients in the developed world have MPS VI and an estimated 3,000 patients in the developed world have MPS I.

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises three approved products and multiple clinical and preclinical product candidates. Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan(R) (sapropterin dihydrochloride) Tablets, a product for the treatment of phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany. Other product candidates include 6R-BH4 for cardiovascular in
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. BioMarin to Host Research and Development Day June 5th
2. BioMarin to Present at the Bank of America Healthcare Conference
3. BioMarin Announces First Quarter 2008 Financial Results
4. BioMarin to Present at the Morgan Stanley Healthcare Conference
5. BioMarin to Host First Quarter 2008 Financial Results Conference Call and Webcast on Tuesday, April 29 at 5:00 p.m. ET (23:00 CET)
6. BioMarin Announces Fourth Quarter and Full Year 2007 Financial Results
7. BioMarin to Present at the Merrill Lynch 2008 Global Healthcare Conference
8. BioMarin Appoints Dr. Gordon Vehar, Vice President of Research
9. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
10. BioMarin and IGAN Biosciences to Collaborate on Development of an Enzyme Therapy to Treat IgA Nephropathy, a Rare and Life-Threatening Kidney Disease
11. BioMarin to Present at the Rodman & Renshaw 9th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , Not for release, publication or distribution (in whole ... to do so would constitute a violation of the relevant ... the "Company") (LSE: SHP, NASDAQ: SHPG ) notes ... a meeting with representatives of AbbVie. This statement ... approval of AbbVie. A further update will be ...
(Date:7/11/2014)... 2014 Research and Markets  has announced ... - Global Industry Analysis, Size, Share, Growth, Trends and ... http://photos.prnewswire.com/prnh/20130307/600769 Transfection ... DNA or RNA) into cells. This technology helps the ... and protein metabolism by affecting the nuclear genes. The ...
(Date:7/11/2014)... BCC Research ( http://www.bccresearch.com ) reveals in its ... TECHNOLOGY: GLOBAL MARKETS , the global market for digital ... in 2013. This is estimated to grow to $490 ... rate (CAGR) of 28.6%. , New digital PCR technology ... within the broader PCR field. The opportunities presented by ...
(Date:7/11/2014)... July 11, 2014 EPFL and ... the appointment of John P. Donoghue . The ... Geneva . The new Wyss ... in Geneva , has named as ... John P. Donoghue , founder of Brown University,s ...
Breaking Biology Technology:Shire plc - Statement re: Media Speculation 2International Transfection Technology Market - Industry Analysis, Size, Share, Growth, Trends and Forecast to 2019 2Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 2Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 3John P. Donoghue is Taking the Lead at the Wyss Center and is Appointed Professor at EPFL and University of Geneva 2John P. Donoghue is Taking the Lead at the Wyss Center and is Appointed Professor at EPFL and University of Geneva 3
... Journal? During the course of any week, in my role ... as VP of CCC, I meet many interesting entrepreneurs, IT ... luncheons and events from which I desire to share my ... we can have some fun revisiting my experiences. My first ...
... development of new drugs as science's most significant ... networks are making it possible to detect outbreaks ... profiling are enabling doctors to identify patients at ... "From Fail and Fix to Predict and Prevent ...
... Rogue Access Point Exposures , ,IBM today ... comprehensive intrusion detection services designed to help customers ... networks. , ,IBM's wireless intrusion detection service ... Global Services' security and business continuity capabilities with ...
Cached Biology Technology:Mr. Jackson Goes to Washington 2Mr. Jackson Goes to Washington 3Mr. Jackson Goes to Washington 4Symposium To Explore Information Technology's Impact on Improving Quality, Cost Effectiveness of Healthcare 2IBM Develops Wireless Security Service 2
(Date:7/11/2014)... OAK RIDGE, Tenn., July 11, 2014--Researchers at the ... received eight R&D 100 awards, presented by R&D ... innovations. , "These awards recognize the tremendous ... Energy Ernest Moniz. "Research and development at the ... its energy challenges and pursue the scientific and ...
(Date:7/11/2014)... many fires burning in eastern New South Wales, Australia ... , At 03:35 UTC on July 11 (12:35 p.m. ... passed over eastern New South Wales (NSW), the Moderate ... image of the region and spotted smoke (light brown) ... thermal bands, are outlined in red. , The New ...
(Date:7/11/2014)... Canyon fire started near the City of Entiat on ... resources, the fire quickly grew to over 1,000 acres ... the fire is under investigation by the Washington Department ... with existing local resources in developing fire control strategies ... (USFS), Washington State Department of Natural Resources, (WA DNR), ...
Breaking Biology News(10 mins):ORNL wins eight R&D 100s 2ORNL wins eight R&D 100s 3ORNL wins eight R&D 100s 4
... to be very different have evolved some sexual reproduction ... also suggest that in the microbial world sex and ... this week in the online journal mBio . ... species to promote genetic exchange are distinct, recent studies ...
... of an international competition organized at Penn State University ... today. The winners, whose awards include a share of ... of awardees in a series of competitions organized by ... Daniel Cosgrove, the Eberly Chair of Biology at Penn ...
... discovered the reason why some people who eat a high-fat ... The study, led in Australia by the Monash Obesity and ... causes brain cells to become insulated from the body preventing ... to burn energy, from reaching the brain efficiently. ...
Cached Biology News:Linking microbial sex and virulence 2Winners of plant-biology video contest announced -- new competition begins at Penn State University 2Brain cells determine obesity -- not lack of willpower: Study 2
Anti human PPAR gamma2 mouse monoclonal antibody...
Mouse monoclonal [RIZ1723] to PRDM2/RIZ...
... Reacts with an early protein. ... 3 hours post-infection exhibiting an ... peak intensity between 6-24 hours. ... intense coarsely granular staining. ...
Goat polyclonal to DRAK2...
Biology Products: